RCT: Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D).

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India – The Lancet

Invited Commentary: DNA vaccines join the fight against COVID-19 – The Lancet

Commentary on Twitter

DNA-based #COVID19 vaccine, ZyCoV-D, demonstrates efficacy, safety, and immunogenicity, according to interim analysis of phase 3 trial conducted in India.

More: https://t.co/bI2eXdbOvB pic.twitter.com/tMuHrA1kz6

— The Lancet (@TheLancet) April 2, 2022